- Stocks
- Pharma & Healthcare
- Zenith Health
Zenith Health share price
NSE: ZENITHHEPharma & HealthcareDrug Manufacturers - Specialty & Generic
Zenith Health at a glance
With a market capitalisation of ₹17 Cr, it ranks 3678th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 0.9% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹3 Cr (−23.6% year on year) and net profit −₹0 Cr (−409.1%), on a standalone basis. Promoters held 28.74% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹17 CrRank 3678 on NSE
- Price to book
- 3.03×FY25
- EPS (TTM)
- ₹0.01to Q4 FY26
- ROE
- 0.9%FY25
- ROCE
- 3.9%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 0.6%FY25
- Book value / share
- ₹1.38FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Zenith Health quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr |
| Revenue YoY | −36.1% | −13.2% | −40.6% | +11.7% | +22.6% | −25.1% | +7.4% | −23.6% |
| Net profit | ₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr | ₹0 Cr | −₹0 Cr |
| Net profit YoY | −38.5% | −25.0% | −390.0% | — | −112.5% | +55.6% | — | −409.1% |
| Net margin | 6.2% | 3.0% | −12.6% | 3.2% | −0.6% | 6.2% | 8.9% | −13.0% |
| EPS | ₹0.03 | ₹0.02 | −₹0.05 | ₹0.02 | ₹0.00 | ₹0.03 | ₹0.04 | −₹0.06 |
Zenith Health financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹12 Cr | ₹14 Cr | ₹22 Cr | ₹13 Cr | ₹14 Cr | ₹11 Cr |
| Operating profit | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| EPS (₹) | ₹0.11 | ₹0.08 | ₹0.06 | ₹0.01 | ₹0.04 | ₹0.01 |
| Cash from operations | ₹2 Cr | −₹1 Cr | ₹1 Cr | −₹1 Cr | ₹2 Cr | ₹1 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹6 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr |
Zenith Health shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 28.74% | 28.74% | 28.74% | 28.74% | 28.74% | 28.74% |
| Domestic institutions | 0.39% | 0.39% | 0.39% | 0.39% | 0.39% | 0.39% |
| Non-institutions | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% |
Zenith Health vs peers
The listed Pharma & Healthcare companies nearest to Zenith Health by market capitalisation.
Ask anything about Zenith Health
Pivot answers on the live chart with evidence you can check, and tests strategies against ZENITHHE's own history. Try: “Why has ZENITHHE moved over the last three months?” · “Backtest a 50-day moving-average crossover on ZENITHHE over five years” · “Compare ZENITHHE with DESHRAK on margins and valuation”
Frequently asked questions about Zenith Health
What is the market cap of Zenith Health?
Zenith Health's market capitalisation is ₹17 Cr (₹17 Cr) at the 22 Oct 2026 close, ranking 3678th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Zenith Health?
Return on equity was 0.9% in FY25 and return on capital employed was 3.9% in FY25 (standalone figures).
Is Zenith Health a debt-free company?
Zenith Health is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were Zenith Health's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Zenith Health reported revenue of ₹3 Cr, −23.6% year on year, and net profit of −₹0 Cr, −409.1% year on year.
What is the shareholding pattern of Zenith Health?
As of 30 Jun 2026: promoters 28.74%, domestic institutions 0.39%, non-institutions 70.87%.
Who are Zenith Health's competitors?
The listed Pharma & Healthcare companies closest to Zenith Health by market cap are Desh Rakshak, Nidan Lab, Vanta Bioscienc, Venmax Drugs, Family Care Hos and Colinz Labs.
Is Zenith Health a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Zenith Health's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ZENITHHE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with Z · all NSE stocks · this page as text